Core Viewpoint - Investors in Reckitt Benckiser Group PLC have until August 4, 2025, to file lead plaintiff applications in a securities class action lawsuit due to alleged failures in disclosing material information during the Class Period from January 13, 2021, to July 28, 2024 [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that Reckitt and certain executives failed to disclose material information, violating federal securities laws [3]. - Specific allegations include that preterm infants were at an increased risk of developing necrotizing enterocolitis (NEC) from consuming the company's cow's milk-based formula, Enfamil, which could impact sales and expose the company to legal claims [4]. - The lawsuit is titled Elevator Constructors Union Local No. 1 Annuity & 401(K) Fund v. Reckitt Benckiser Group PLC, et al., No. 25-cv-4708 [5]. Group 2: ClaimsFiler Information - ClaimsFiler is a free shareholder information service aimed at helping retail investors recover funds from securities class action settlements [6]. - The platform allows investors to register for free, access information on various securities class action cases, upload portfolio transactional data, and submit inquiries for free case evaluations [6].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Reckitt Benckiser Group plc regarding a class action lawsuit related to misleading statements and omissions concerning the safety of its Enfamil formula for preterm infants [1][3]. Group 1: Allegations and Class Period - The class period for the lawsuit is defined as January 13, 2021, to July 28, 2024 [3]. - Allegations include that Reckitt's cow's milk-based formula, Enfamil, posed an increased risk of necrotizing enterocolitis (NEC) in preterm infants, which was not disclosed [3]. - The lawsuit claims that Reckitt's positive statements about its business and operations were materially false and misleading due to the undisclosed risks and potential legal claims [3]. Group 2: Shareholder Actions and Deadlines - Shareholders are encouraged to register for the class action by August 4, 2025, to participate in potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights who have suffered losses due to deceit and illegal business practices [5]. - The firm emphasizes the importance of responsible business practices and corporate citizenship [5]. - The firm seeks recovery for investors affected by misleading statements that led to artificial inflation of the company's stock [5].

Group 1 - A class action lawsuit has been filed against Reckitt Benckiser Group Plc for alleged securities fraud and unlawful business practices [2][4] - Investors who purchased Reckitt securities during the Class Period have until August 4, 2025, to request appointment as Lead Plaintiff [2] - Reckitt's American Depositary Share (ADS) price experienced significant declines following jury verdicts related to its subsidiary Mead Johnson's negligence in warning about health risks associated with its products [4][5] Group 2 - On March 15, 2024, an Illinois jury awarded $60 million against Reckitt's Mead Johnson subsidiary for failing to warn about the risk of necrotizing enterocolitis (NEC) in preterm infants, leading to a nearly 14% drop in Reckitt's ADS price [4] - A subsequent lawsuit against Abbott Laboratories resulted in a $495 million award, similarly impacting Reckitt's ADS price with a nearly 9% decline [5] - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [6]

Core Viewpoint - A class action securities lawsuit has been filed against Reckitt Benckiser Group plc, alleging securities fraud that negatively impacted investors between January 13, 2021, and July 28, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Reckitt Benckiser Group plc made false statements regarding the safety of its cow's milk-based formula, Enfamil, particularly concerning the increased risk of necrotizing enterocolitis (NEC) in preterm infants [2]. - It is alleged that these misleading statements affected Reckitt's sales of Enfamil and exposed the company to legal claims, undermining the positive assertions made about its business and operations [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 4, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Group 1 - Mama's Creations, Inc. (MAMA) is currently ranked 14 in the Zacks Sector Rank among 178 companies in the Consumer Staples group [2] - MAMA has a Zacks Rank of 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - The stock has increased approximately 10.8% year-to-date, outperforming the Consumer Staples sector average return of 6.8% [4] Group 2 - MAMA belongs to the Food - Miscellaneous industry, which includes 42 companies and is currently ranked 184 in the Zacks Industry Rank [5] - The average performance of stocks in the Food - Miscellaneous industry has declined by 2.9% this year, highlighting MAMA's relative strength [5] - Investors should monitor both Mama's Creations, Inc. and Reckitt Benckiser Group PLC for their potential to sustain strong performance in the Consumer Staples sector [6]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Reckitt Benckiser Group plc regarding a class action lawsuit alleging misleading statements related to the company's cow's milk-based formula, Enfamil, which may have increased the risk of NEC in preterm infants [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from January 13, 2021, to July 28, 2024 [1]. - The complaint claims that Reckitt failed to disclose that preterm infants were at an increased risk of developing NEC from consuming Enfamil [1]. - It is alleged that Reckitt's positive statements about its business and operations were materially false and misleading due to the undisclosed risks and potential legal claims [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by August 4, 2025, to potentially become lead plaintiffs [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and illegal business practices [3]. - The firm is committed to ensuring companies engage in responsible business practices and good corporate citizenship [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated the company's stock [3].

Core Viewpoint - A class action securities lawsuit has been filed against Reckitt Benckiser Group plc, alleging securities fraud that affected investors between January 13, 2021, and July 28, 2024 [1][2]. Group 1: Allegations - The lawsuit claims that Reckitt's cow's milk-based formula, Enfamil, increased the risk of preterm infants developing NEC, which was not disclosed [2]. - It is alleged that the company concealed the impact of these risks on Enfamil's sales and its exposure to legal claims [2]. - Positive statements made by the defendants regarding the company's business and prospects were claimed to be materially false and misleading [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until August 4, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4]. - The firm has over 70 employees dedicated to serving clients in complex securities litigation [4].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Reckitt Benckiser Group PLC American Depositary Shares (ADSs) of a class action lawsuit with a lead plaintiff deadline of August 4, 2025 [1] Group 1: Class Action Details - The class period for the lawsuit is from January 13, 2021, to July 28, 2024, during which investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][5] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [4] Group 2: Allegations Against Reckitt - The lawsuit alleges that Reckitt failed to warn investors that preterm infants were at an increased risk of developing necrotizing enterocolitis (NEC) from consuming its cow's milk-based formula, Enfamil [5] - It is claimed that Reckitt did not disclose the potential impact on sales of Enfamil and the company's exposure to legal claims, leading to materially false and misleading statements about its business and operations [5]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Reckitt Benckiser Group plc regarding a class action lawsuit related to misleading statements about the company's cow's milk-based formula, Enfamil, which allegedly increased the risk of NEC in preterm infants [1][3]. Group 1: Class Action Details - The class period for the lawsuit is from January 13, 2021, to July 28, 2024 [3]. - Allegations include that Reckitt failed to disclose the increased risk of NEC for preterm infants consuming Enfamil, the impact on sales, and exposure to legal claims, leading to materially false and misleading statements about the company's business and prospects [3]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by the deadline of August 4, 2025, to potentially become lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - A class action lawsuit has been filed against Reckitt Benckiser Group PLC for alleged violations of federal securities laws related to misleading statements about the company's products and their safety [1][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased Reckitt securities between January 13, 2021, and July 28, 2024, inclusive [2]. - The complaint alleges that Reckitt's officers made materially false and misleading statements regarding the safety of its cow's milk-based formula, Enfamil, particularly concerning the risk of necrotizing enterocolitis (NEC) in preterm infants [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Reckitt have until August 4, 2025, to request to be appointed as lead plaintiff in the case [4]. - Participation in any recovery does not require serving as lead plaintiff [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorneys' fees if successful [5]. - The firm has a history of recovering hundreds of millions of dollars for investors in securities fraud class actions [6].